BRPI0813898A2 - métodos para selecionar um peptídeo ou polipeptídeo resistente à protease de um repertório de peptídeo ou polipeptídeos, para produzir um repertório de peptídeos ou polipeptídeos resistentes à protease, para fabricar um peptídeo ou polipeptídeo resistente à protease, e para tratar uma doença, peptídeo ou polipeptídeo resistente à protease, domínio variável simples de imunoglobulina resistente à protease isolada, antagonista, uso de um antagonista, ácido nucleico, vetor, e, célula hospedeira. - Google Patents

métodos para selecionar um peptídeo ou polipeptídeo resistente à protease de um repertório de peptídeo ou polipeptídeos, para produzir um repertório de peptídeos ou polipeptídeos resistentes à protease, para fabricar um peptídeo ou polipeptídeo resistente à protease, e para tratar uma doença, peptídeo ou polipeptídeo resistente à protease, domínio variável simples de imunoglobulina resistente à protease isolada, antagonista, uso de um antagonista, ácido nucleico, vetor, e, célula hospedeira.

Info

Publication number: BRPI0813898A2
Authority: BR; Brazil
Prior art keywords: polypeptide; peptide; protease; resistant; antagonist
Prior art date: 2007-06-06

Application number

BRPI0813898A

Other languages

English (en)

Inventor

Enever Carolyn

Tomlinson Ian

Jespers Laurent

Pupecka Malgorzata

Original Assignee

Domantis Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-06

Filing date

2008-06-03

Publication date

2019-09-24

2008-06-03 Application filed by Domantis Ltd filed Critical Domantis Ltd

2019-09-24 Publication of BRPI0813898A2 publication Critical patent/BRPI0813898A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Otolaryngology (AREA)
Heart & Thoracic Surgery (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Virology (AREA)
Dispersion Chemistry (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Microbiology (AREA)
Mycology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)

BRPI0813898A 2007-06-06 2008-06-03 métodos para selecionar um peptídeo ou polipeptídeo resistente à protease de um repertório de peptídeo ou polipeptídeos, para produzir um repertório de peptídeos ou polipeptídeos resistentes à protease, para fabricar um peptídeo ou polipeptídeo resistente à protease, e para tratar uma doença, peptídeo ou polipeptídeo resistente à protease, domínio variável simples de imunoglobulina resistente à protease isolada, antagonista, uso de um antagonista, ácido nucleico, vetor, e, célula hospedeira. BRPI0813898A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US93363207P	2007-06-06	2007-06-06
GBGB0724331.4A GB0724331D0 (en)	2007-12-13	2007-12-13	Compositions for pulmonary delivery
PCT/GB2008/050399 WO2008149143A2 (en)	2007-06-06	2008-06-03	Methods for selecting protease resistant polypeptides

Publications (1)

Publication Number	Publication Date
BRPI0813898A2 true BRPI0813898A2 (pt)	2019-09-24

Family

ID=39016531

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0813898A BRPI0813898A2 (pt)	2007-06-06	2008-06-03	métodos para selecionar um peptídeo ou polipeptídeo resistente à protease de um repertório de peptídeo ou polipeptídeos, para produzir um repertório de peptídeos ou polipeptídeos resistentes à protease, para fabricar um peptídeo ou polipeptídeo resistente à protease, e para tratar uma doença, peptídeo ou polipeptídeo resistente à protease, domínio variável simples de imunoglobulina resistente à protease isolada, antagonista, uso de um antagonista, ácido nucleico, vetor, e, célula hospedeira.

Country Status (7)

Country	Link
US (7)	US20100254995A1 (pt)
EP (3)	EP2162465A2 (pt)
JP (3)	JP2010528646A (pt)
CN (1)	CN101848935A (pt)
BR (1)	BRPI0813898A2 (pt)
GB (1)	GB0724331D0 (pt)
WO (3)	WO2008149143A2 (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
US8188223B2 (en)	2005-05-18	2012-05-29	Ablynx N.V.	Serum albumin binding proteins
DE102005023617A1 (de)	2005-05-21	2006-11-23	Aspre Ag	Verfahren zum Mischen von Farben in einem Display
JP5308328B2 (ja)	2006-04-04	2013-10-09	シングレックス，インコーポレイテッド	トロポニンの分析のための高感度のシステムおよび方法
US7838250B1 (en)	2006-04-04	2010-11-23	Singulex, Inc.	Highly sensitive system and methods for analysis of troponin
JP2010528647A (ja) *	2007-06-06	2010-08-26	ドマンティスリミテッド	ポリペプチド、抗体可変ドメインおよびアンタゴニスト
WO2009127691A1 (en)	2008-04-17	2009-10-22	Ablynx N.V.	Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
EP2271323A2 (en)	2008-05-06	2011-01-12	Glaxo Group Limited	Encapsulation of biologically active agents
KR20110091777A (ko) *	2008-11-26	2011-08-12	글락소 그룹 리미티드	폴리펩티드, 항체 가변 도메인 및 길항제
EP2364326B1 (en)	2008-12-05	2018-07-04	Glaxo Group Limited	Methods for selecting protease resistant polypeptides
WO2010081787A1 (en)	2009-01-14	2010-07-22	Domantis Limited	IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
EP2398825B1 (en) *	2009-02-19	2017-10-25	Glaxo Group Limited	Single variable domain against serum albumin
AU2010215479B2 (en)	2009-02-19	2015-01-22	Glaxo Group Limited	Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists
EP3656788A3 (en)	2009-02-19	2020-07-29	Glaxo Group Limited	Improved anti-serum albumin binding variants
EP2401296A1 (en)	2009-02-24	2012-01-04	Glaxo Group Limited	Multivalent and/or multispecific rankl-binding constructs
CA2753287A1 (en)	2009-02-24	2010-09-02	Glaxo Group Limited	Antigen-binding constructs
CN104127880A (zh) *	2009-03-27	2014-11-05	葛兰素集团有限公司	药用融合体和缀合物
WO2010144358A1 (en)	2009-06-08	2010-12-16	Singulex, Inc.	Highly sensitive biomarker panels
WO2011008814A2 (en)	2009-07-14	2011-01-20	Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation	Multiplexed measurement of exogenous and endogenous dna
JP2012532619A (ja) *	2009-07-16	2012-12-20	グラクソグループリミテッド	Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
KR20120063475A (ko)	2009-07-29	2012-06-15	글락소 그룹 리미티드	항-ｔｇｆ-베타 수용체 타입 ⅱ 단일 도메인 항체
CN104147611A (zh) *	2009-09-30	2014-11-19	葛兰素集团有限公司	具有延长的半衰期的药物融合体和缀合物
JP2013507978A (ja) *	2009-10-27	2013-03-07	グラクソグループリミテッド	安定な抗ｔｎｆｒ１ポリペプチド、抗体可変ドメイン及びアンタゴニスト
JP2013518558A (ja) *	2010-02-04	2013-05-23	メディカルリサーチカウンシル	構造化されたペプチドプロセシング
EP2531523A1 (en)	2010-02-05	2012-12-12	Ablynx N.V.	Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
EP2571900A1 (en)	2010-05-20	2013-03-27	Glaxo Group Limited	Improved anti-serum albumin binding variants
US9012609B2 (en)	2010-08-13	2015-04-21	Glaxosmithkline Intellectual Property Development Limited	Anti-serum albumin binding variants
WO2012022703A2 (en)	2010-08-20	2012-02-23	Glaxo Group Limited	Improved anti-serum albumin binding variants
CA2809089C (en)	2010-08-23	2018-12-18	Board Of Regents, The University Of Texas System	Anti-ox40 antibodies and methods of using the same
US9518132B2 (en)	2010-11-09	2016-12-13	Altimab Therapeutics, Inc.	Protein complexes for antigen binding and methods of use
AU2011333738A1 (en) *	2010-11-24	2013-07-11	Glaxo Group Limited	Multispecific antigen binding proteins targeting HGF
CN102121043B (zh) *	2010-12-16	2013-06-05	东华大学	一种亲和筛选菠萝蛋白酶的亲和配基的方法
WO2012093125A1 (en)	2011-01-06	2012-07-12	Glaxo Group Limited	Ligands that bind tgf-beta receptor ii
HUE038848T2 (hu)	2011-04-21	2018-11-28	Bristol Myers Squibb Co	CD40-antagonista antitest polipeptidek
JP5987057B2 (ja) *	2011-07-27	2016-09-06	グラクソグループリミテッドＧｌａｘｏＧｒｏｕｐＬｉｍｉｔｅｄ	Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン
PE20141522A1 (es) *	2011-08-17	2014-11-17	Glaxo Group Ltd	Proteinas y peptidos modificados
WO2014048977A1 (en) *	2012-09-25	2014-04-03	Affibody Ab	Albumin binding polzpeptide
CN104903349B (zh) *	2012-11-08	2018-10-19	十一生物治疗股份有限公司	Il-6拮抗剂及其应用
EP3113796A1 (en)	2014-03-07	2017-01-11	Bristol-Myers Squibb Company	Method of using antibody polypeptides that antagonize cd40 to treat ibd
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MA41374A (fr) *	2015-01-20	2017-11-28	Cytomx Therapeutics Inc	Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
CA3255406A1 (en)	2015-03-31	2025-07-03	Sorriso Pharmaceuticals, Inc.	Tnf-alpha binding polypeptides
WO2016156468A1 (en) *	2015-03-31	2016-10-06	Vhsquared Limited	Polypeptides
SG11201706840WA (en)	2015-03-31	2017-09-28	Vhsquared Ltd	Peptide construct having a protease-cleavable linker
CN108348572B (zh)	2015-03-31	2021-06-29	日东制药株式会社	含有融合组织穿透肽和抗-vegf制剂的融合蛋白的预防和治疗眼疾的药物组合物
EP3345613B1 (en)	2015-09-01	2023-05-10	Il Dong Pharmaceutical Co., Ltd.	Composition for use in treating cancer or an angiogenesis-related disease comprising a fusion protein of a tumor-penetrating peptide and an anti-vegf agent
KR20250057128A (ko)	2015-12-30	2025-04-28	코디악 사이언시스 인코포레이티드	항체 및 이의 접합체
EP3405491A1 (en) *	2016-01-21	2018-11-28	VHsquared Limited	Polypeptides
SG11201807402PA (en)	2016-03-31	2018-09-27	Vhsquared Ltd	Compositions
EP3519438A1 (en)	2016-09-30	2019-08-07	VHsquared Limited	Compositions
US10337070B2 (en)	2017-01-12	2019-07-02	Cardioforecast Ltd.	Methods and kits for treating cardiovascular disease
CN107376036B (zh) *	2017-06-23	2020-01-07	淮阴工学院	一种酶响应型多功能纳米涂层的构建方法
EP3758737A4 (en)	2018-03-02	2022-10-12	Kodiak Sciences Inc.	IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
CA3115772A1 (en) *	2018-10-09	2020-04-16	Sung Jin Park	Engineered fibroblast growth factor variants as receptor antagonists
CN109234298A (zh) *	2018-10-30	2019-01-18	南昌大学	一种卷曲乳杆菌atcc55221的构建及其在治疗产妇乳头皲裂中的应用
CA3120327A1 (en)	2018-12-06	2020-06-11	Cytomx Therapeutics, Inc.	Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
KR20220063148A (ko)	2019-06-21	2022-05-17	소리소 파마슈티컬스 인크.	조성물
US12559552B2 (en)	2019-06-21	2026-02-24	Sorriso Pharmaceuticals, Inc.	IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
CA3144567A1 (en) *	2019-06-21	2020-12-24	Scott Crowe	Polypeptides
CA3157509A1 (en)	2019-10-10	2021-04-15	Kodiak Sciences Inc.	Methods of treating an eye disorder
US20220288226A1 (en) *	2020-08-27	2022-09-15	Enosi Life Sciences Corp.	Methods and compositions to treat autoimmune diseases and cancer
CA3193273A1 (en)	2020-08-27	2022-03-03	Enosi Therapeutics Corporation	Methods and compositions to treat autoimmune diseases and cancer
WO2022117569A1 (en)	2020-12-02	2022-06-09	Oncurious Nv	A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2025049818A1 (en)	2023-08-29	2025-03-06	Enosi Therapeutics Corporation	Tnfr1 antagonists lacking agonist activity and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2148299B (en)	1983-09-01	1988-01-06	Hybritech Inc	Antibody compositions of therapeutic agents having an extended serum half-life
EP0368684B2 (en)	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
CA2016842A1 (en)	1989-05-16	1990-11-16	Richard A. Lerner	Method for tapping the immunological repertoire
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
DK0585287T3 (da)	1990-07-10	2000-04-17	Cambridge Antibody Tech	Fremgangsmåde til fremstilling af specifikke bindingsparelementer
PT1024191E (pt)	1991-12-02	2008-12-22	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU2002219944B2 (en)	2000-11-28	2008-02-21	Medimmune, Llc	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20060073141A1 (en) *	2001-06-28	2006-04-06	Domantis Limited	Compositions and methods for treating inflammatory disorders
GB0118689D0 (en)	2001-08-01	2001-09-19	Psimedica Ltd	Pharmaceutical formulation
JP2005526769A (ja) *	2002-03-15	2005-09-08	ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド	治療剤を全身搬送するための中央気道投与
AU2003244817B2 (en) *	2002-06-28	2010-08-26	Domantis Limited	Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US7696320B2 (en) *	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060002935A1 (en) *	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
JP4601426B2 (ja)	2002-09-06	2010-12-22	アレクシオンファーマシューティカルズ，インコーポレイテッド	補体成分ｃ５に対する抗体を使用する喘息の処置の方法
KR101317045B1 (ko)	2002-09-06	2013-10-16	암젠 인코포레이티드	치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
EP1578801A2 (en) *	2002-12-27	2005-09-28	Domantis Limited	Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230203D0 (en) *	2002-12-27	2003-02-05	Domantis Ltd	Fc fusion
DE602004017726D1 (de) *	2003-06-30	2008-12-24	Domantis Ltd	Pegylierte Single-domain-antikörper (dAb)
MX2007006593A (es)	2004-12-02	2008-03-04	Domantis Ltd	Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
GB0521621D0 (en) *	2005-10-24	2005-11-30	Domantis Ltd	Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
JP2009519011A (ja)	2005-12-01	2009-05-14	ドマンティスリミテッド	インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
EA200801166A1 (ru)	2005-12-01	2008-12-30	Домантис Лимитед	Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
AU2006323412A1 (en) *	2005-12-06	2007-06-14	Domantis Limited	Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
HUE048024T2 (hu)	2006-08-10	2020-05-28	Roy C Levitt	Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
CA2667466A1 (en)	2006-10-27	2008-05-02	Ablynx N.V.	Intranasal delivery of polypeptides and proteins
JP2010528647A (ja)	2007-06-06	2010-08-26	ドマンティスリミテッド	ポリペプチド、抗体可変ドメインおよびアンタゴニスト
CA2688433A1 (en)	2007-06-06	2008-12-11	Domantis Limited	Methods for selecting protease resistant polypeptides

2007
- 2007-12-13 GB GBGB0724331.4A patent/GB0724331D0/en not_active Ceased
2008
- 2008-06-03 US US12/663,501 patent/US20100254995A1/en not_active Abandoned
- 2008-06-03 WO PCT/GB2008/050399 patent/WO2008149143A2/en not_active Ceased
- 2008-06-03 JP JP2010510883A patent/JP2010528646A/ja active Pending
- 2008-06-03 EP EP08750794A patent/EP2162465A2/en not_active Withdrawn
- 2008-06-03 JP JP2010510882A patent/JP2010528645A/ja active Pending
- 2008-06-03 US US12/663,498 patent/US8357780B2/en active Active
- 2008-06-03 US US12/663,491 patent/US20100254972A1/en not_active Abandoned
- 2008-06-03 WO PCT/GB2008/050400 patent/WO2008149144A2/en not_active Ceased
- 2008-06-03 EP EP08750795A patent/EP2162466A2/en not_active Withdrawn
- 2008-06-03 JP JP2010510884A patent/JP2010529840A/ja active Pending
- 2008-06-03 BR BRPI0813898A patent/BRPI0813898A2/pt not_active IP Right Cessation
- 2008-06-03 US US12/663,509 patent/US20110086019A1/en not_active Abandoned
- 2008-06-03 WO PCT/GB2008/050403 patent/WO2008149146A2/en not_active Ceased
- 2008-06-03 CN CN200880102138A patent/CN101848935A/zh active Pending
- 2008-06-03 EP EP08750798A patent/EP2158218A2/en not_active Withdrawn
2013
- 2013-02-11 US US13/763,768 patent/US9562090B2/en not_active Expired - Fee Related
2016
- 2016-12-21 US US15/386,141 patent/US10072089B2/en active Active
2018
- 2018-07-27 US US16/047,197 patent/US20190040148A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2008149144A3 (en)	2009-04-02
US8357780B2 (en)	2013-01-22
US20100254995A1 (en)	2010-10-07
US20170174775A1 (en)	2017-06-22
GB0724331D0 (en)	2008-01-23
CN101848935A (zh)	2010-09-29
US9562090B2 (en)	2017-02-07
US20100254972A1 (en)	2010-10-07
JP2010528646A (ja)	2010-08-26
US10072089B2 (en)	2018-09-11
WO2008149143A3 (en)	2009-04-02
US20190040148A1 (en)	2019-02-07
US20140141093A1 (en)	2014-05-22
US20110086019A1 (en)	2011-04-14
WO2008149144A2 (en)	2008-12-11
JP2010528645A (ja)	2010-08-26
WO2008149146A2 (en)	2008-12-11
EP2158218A2 (en)	2010-03-03
US20100260763A1 (en)	2010-10-14
WO2008149143A2 (en)	2008-12-11
JP2010529840A (ja)	2010-09-02
WO2008149146A3 (en)	2009-06-11
EP2162466A2 (en)	2010-03-17
EP2162465A2 (en)	2010-03-17

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application fees: dismissal - article 86 of industrial property law
2020-01-21	B08K	Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0813898A2 (pt)	2019-09-24	métodos para selecionar um peptídeo ou polipeptídeo resistente à protease de um repertório de peptídeo ou polipeptídeos, para produzir um repertório de peptídeos ou polipeptídeos resistentes à protease, para fabricar um peptídeo ou polipeptídeo resistente à protease, e para tratar uma doença, peptídeo ou polipeptídeo resistente à protease, domínio variável simples de imunoglobulina resistente à protease isolada, antagonista, uso de um antagonista, ácido nucleico, vetor, e, célula hospedeira.
KR102225278B9 (ko)	2021-10-27	질의되는 개체와 관련되는 질병, 유전자 또는 단백질을 예측하는 방법 및 이를 이용하여 구축되는 예측 시스템
CY1124341T1 (el)	2022-07-22	Ποντικοι me εξανθρωπισμενη καθολικη ελαφρια αλυσιδα
BRPI0905076A2 (pt)	2015-07-07	Polipeptídeo, anticorpo, região variável, cadeia pesada ou cadeia leve, gene, vetor, célula hospedeira, método para produzir o referido polipeptídeo, e composição farmacêutica compreendendo o mesmo
BRPI0814781A2 (pt)	2014-10-21	Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI0813242A2 (pt)	2015-08-18	Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição.
EP3636761A4 (en)	2021-03-03	ANTIGIBINDING PEPTIDE WITH DETECTION OF MAGE-A4 DERIVED PEPTIDE
IL282981A (en)	2021-06-30	Compositions, methods and systems for protein corona analysis and uses thereof
BRPI0808104A2 (pt)	2015-03-24	Métodos para preparar e para produzir um polipeptídeo, polipeptídeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, e, célula hospedeira recombinante
MA53094A (fr)	2021-05-12	Protéine de liaison à l'antigène anti-steap1
IL290257A (en)	2022-04-01	Systems and methods for sample preparation, data generation, and protein corona analysis
EP3752191A4 (en)	2021-12-22	NON-VIRAL DNA VECTORS AND ASSOCIATED USES FOR THE PRODUCTION OF ANTIBODIES AND FUSION PROTEINS
BRPI0813216A2 (pt)	2014-12-23	Inibidores de proteínas cinases e métodos para usá-los.
CR10652A (es)	2009-05-13	Anticuerpos monoclonales humanos especificos para light humano antagonistas
WO2010088411A3 (en)	2010-09-16	Conformationally dynamic peptides
EA201270553A1 (ru)	2012-09-28	Ингибиторы тирозинкиназы брутона
EP3150750A3 (en)	2017-05-24	Peptide constructs and assay systems
BRPI1009576A2 (pt)	2016-03-08	anticorpo, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, uso de um anticorpo, e, método para o tratamento de um paciente.
BRPI0814296A2 (pt)	2014-10-21	Polipeptídeo isolado, seqüência de nucleotídeos, vetor, célula hospedeira, e, uso do polipeptídeo, da seqüência de nucleotídeos, do vetor ou da célula hospedeira
PH12015502849B1 (en)	2019-07-17	Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
PL2140269T3 (pl)	2014-07-31	Podpis białkowy/znaczniki do wykrywania gruczolakoraka
BRPI0814127A2 (pt)	2015-02-03	Polipeptídeos imunegênicos e anticorpos monoclonais
BRPI0921907A2 (pt)	2015-08-25	Vetor de transferência para inserir um gene em um local genético de uma seqüência de baculovírus, métodos para produzir um bacmid recombinante, um baculovírus recombinante, e, uma ou mais proteínas, bacmid recombinante, baculovírus recombinante, e, célula.
DE112015000512A5 (de)	2017-03-30	Hybridom-Zelllinie (My-C-cC0C2-235-3H8) und deren Verwendung zur Herstellung eines monoklonalen Antikörpers gegen das humane, herzspezifische Myosin Bindung Protein C (C-protein), MYBPC3, cMyBP-C oder My-C)